Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : LX-96
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Symbiosis Pharmaceutical Services
Deal Size : $10.0 million
Deal Type : Financing
Paradox Gets $10M from SymBiosis to Advance Protein Misfolding Disease Therapies
Details : The financing will be used to advance Paradox’s therapeutic pipeline, which includes LX-96, a monoclonal antibody designed for the treatment of late-stage immunoglobulin light chain (AL) amyloidosis.
Product Name : LX-96
Product Type : Antibody
Upfront Cash : Undisclosed
February 25, 2025
Lead Product(s) : LX-96
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Symbiosis Pharmaceutical Services
Deal Size : $10.0 million
Deal Type : Financing
Reset All
